

AISAP - empowering physicians with AI at the point-of-care Roni Attali, Adiel Amshalom, Robert Klempfner, Ehud Raanani, Elad Maor Aisap www.aisap.ai Roni Attali

Health IT/Digital SESSIONS • Is AI revolutionizing drug discovery and clinical development? • Digital health role in 2024 and forward

- o Executive Summary: AISAP is the innovative creation of technological cyber experts and senior cardiologists at Sheba MC. AISAP developed an AI-based platform (POCAD™) enabling physicians to acquire and interpret images with high accuracy, revolutionizing the diagnostic process while improving health equity and clinical outcomes. POCAD supports the use of handheld ultrasound devices, providing real-time acquisition guidance and facilitating immediate, accurate interpretation. ;

- o Core Technology The first product, CARDIO V1.0, a cardiac diagnostic package, enables automatic diagnosis of major cardiac findings within five minutes. AISAP's algorithms were trained on millions of video clips and validated in multiple trials on thousands of patients, establishing outstanding performance and accuracy levels. Expanding POCAD™ to multi-organ diagnostic support system will lead to vastly improved clinical outcomes and healthcare efficiency.

- o Product Profile/Pipeline: CARDIO V1.0 received Israeli regulatory approval and started sales in Israeli hospitals. An FDA-approved prospective study for the product was completed and the product was submitted for FDA approval in Q4 2023. The company is collaborating with several US hospitals for additional clinical trials intended to examine and provide evidencebased support for AISAP's value proposition.

- o Business Strategy: The business model is subscription-based SaaS, tailored for the customer's specific requirements. Subscription includes AI analysis, PACS on cloud, and automated reporting. AISAP aims to streamline patient care, reduce patient length of stay (LOS) and unnecessary tests, accelerate diagnosis and treatment timelines, and enhance safety and patient satisfaction, while optimizing revenue capture through increased utilization of clinically appropriate procedures.

- o What's Next? R&D, Preclinical / Clinicals, Organizational Plans, Financial Plans Aisap is currently developing a multi-organ system of additional products in other anatomical areas. AI-assisted vascular ultrasonography, the second diagnostic package under development, has shown good initial results. Combined, the products are synergistic, aligning with AISAPs vision of empowering care providers to obtain comprehensive imaging scans, anytime anywhere, reaching accurate diagnosis in a timely manner for clinical decision-making.